{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:04:53Z","timestamp":1795111493265,"version":"4.10.3"},"reference-count":173,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2019,7,9]]},"DOI":"10.1161\/cir.0000000000000665","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T05:00:25Z","timestamp":1548651625000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2370,"title":["2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons"],"prefix":"10.1161","volume":"140","author":[{"given":"Craig T.","family":"January","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Samuel","family":"Wann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Calkins","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin E.","family":"Cigarroa","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Joseph C.","family":"Cleveland","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Ellinor","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Field","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Furie","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine T.","family":"Murray","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Shea","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Tracy","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[{"name":"Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. \u2020HRS Representative. \u2021ACC\/AHA Task Force on Clinical Practice Guidelines Liaison. \u00a7STS Representative. \u2016ACC\/AHA Representative. \u00b6ACC\/AHA Task Force on Performance Measures Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2_2","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US)","year":"2011","unstructured":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011."},{"key":"e_1_3_2_2_3_2","volume-title":"Finding What Works in Health Care: Standards for Systematic Reviews","author":"Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US)","year":"2011","unstructured":"Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press; 2011."},{"key":"e_1_3_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000042"},{"key":"e_1_3_2_2_5_2","volume-title":"Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines","author":"ACCF\/AHA Task Force on Practice Guidelines","year":"2010","unstructured":"ACCF\/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http:\/\/assets.cardiosource.com\/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http:\/\/professional.heart.org\/idc\/groups\/ahamah-public\/@wcm\/@sop\/documents\/downloadable\/ucm_319826.pdf. Accessed October 31, 2018."},{"key":"e_1_3_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000312"},{"key":"e_1_3_2_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000090"},{"key":"e_1_3_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31827e8e5f"},{"key":"e_1_3_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000128"},{"key":"e_1_3_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000041"},{"key":"e_1_3_2_3_3_2","unstructured":"ACCF\/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http:\/\/assets.cardiosource.com\/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http:\/\/professional.heart.org\/idc\/groups\/ahamah-public\/@wcm\/@sop\/documents\/downloadable\/ucm_319826.pdf. Accessed October 31 2018."},{"key":"e_1_3_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000312"},{"key":"e_1_3_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31827e8e5f"},{"key":"e_1_3_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002776"},{"key":"e_1_3_2_4_3_2","doi-asserted-by":"crossref","unstructured":"Ezekowitz MD Nagarakanti R Noack H et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016;134:589\u201398.","DOI":"10.1161\/CIRCULATIONAHA.115.020950"},{"key":"e_1_3_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005835"},{"key":"e_1_3_2_4_5_2","article-title":"Indications for anticoagulant and antiplatelet combined therapy.","volume":"359","author":"Floyd CN","year":"2017","unstructured":"Floyd, CN, Ferro, A. Indications for anticoagulant and antiplatelet combined therapy. BMJ. 2017;359:j3782.","journal-title":"BMJ"},{"key":"e_1_3_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"e_1_3_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0175"},{"key":"e_1_3_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.030"},{"key":"e_1_3_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_3_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_3_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002617"},{"key":"e_1_3_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424849900400102"},{"key":"e_1_3_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.3.1469"},{"key":"e_1_3_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330103"},{"key":"e_1_3_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.9.2107"},{"key":"e_1_3_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.1.53"},{"key":"e_1_3_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000031"},{"key":"e_1_3_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000503"},{"key":"e_1_3_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.12.148"},{"key":"e_1_3_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/circep.112.970749"},{"key":"e_1_3_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.896"},{"key":"e_1_3_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sun029"},{"key":"e_1_3_2_4_25_2","article-title":"Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.","author":"Aguilar MI","year":"2005","unstructured":"Aguilar, MI, Hart, R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005.:CD001927.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_3_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04550511"},{"key":"e_1_3_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.022361"},{"key":"e_1_3_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000442877"},{"key":"e_1_3_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.051"},{"key":"e_1_3_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035418"},{"key":"e_1_3_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.09.092"},{"key":"e_1_3_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.553438"},{"key":"e_1_3_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.10.035"},{"key":"e_1_3_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04853.x"},{"key":"e_1_3_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu054"},{"key":"e_1_3_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011415527"},{"key":"e_1_3_2_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011417716"},{"key":"e_1_3_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"e_1_3_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615"},{"key":"e_1_3_2_4_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024057"},{"key":"e_1_3_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.11.004"},{"key":"e_1_3_2_4_43_2","first-page":"888","article-title":"A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.","volume":"38","author":"Fanola CL","year":"2017","unstructured":"Fanola, CL, Giugliano, RP, Ruff, CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017;38:888\u201396.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.061"},{"key":"e_1_3_2_4_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026714"},{"key":"e_1_3_2_4_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.132.suppl_3.17277"},{"key":"e_1_3_2_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.01.004"},{"key":"e_1_3_2_4_48_2","volume-title":"ELIQUIS (apixaban) [package insert]","year":"2012","unstructured":"ELIQUIS (apixaban) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012."},{"key":"e_1_3_2_4_49_2","volume-title":"Savaysa [package insert]","year":"2015","unstructured":"Savaysa [package insert] 2015. Daiichi Sankyo, Inc; Parsippany, NJ."},{"key":"e_1_3_2_4_50_2","doi-asserted-by":"crossref","unstructured":"Nielsen PB Skj\u00f8th F Overvad TF et al. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation. 2018;137:832\u201340.","DOI":"10.1161\/CIRCULATIONAHA.117.029081"},{"key":"e_1_3_2_4_51_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"e_1_3_2_4_52_2","volume-title":"2016 USRDS annual data report: epidemiology of kidney disease in the United States","author":"US Renal Data System","year":"2016","unstructured":"US Renal Data System. 2016 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016."},{"key":"e_1_3_2_4_53_2","doi-asserted-by":"crossref","unstructured":"Sood MM Komenda P Sood AR et al. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009;136:1128\u201333.","DOI":"10.1378\/chest.09-0730"},{"key":"e_1_3_2_4_54_2","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000441","article-title":"Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis.","volume":"3","author":"Nochaiwong S","year":"2016","unstructured":"Nochaiwong, S, Ruengorn, C, Awiphan, R, et al. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016;3:e000441.","journal-title":"Open Heart"},{"key":"e_1_3_2_4_55_2","article-title":"Apixaban use among patients with severe renal impairment.","volume":"48","author":"Deal EN","year":"2014","unstructured":"Deal, EN, Pope, H, Ross, W. Apixaban use among patients with severe renal impairment. Ann Pharmacother. 2014;48:1667.","journal-title":"Ann Pharmacother"},{"key":"e_1_3_2_4_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1905"},{"key":"e_1_3_2_4_57_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016090980"},{"key":"e_1_3_2_4_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12083"},{"key":"e_1_3_2_4_59_2","doi-asserted-by":"crossref","unstructured":"Fauchier L Clementy N Bisson A et al. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated? Stroke. 2016;47:1831\u20136.","DOI":"10.1161\/STROKEAHA.116.013253"},{"key":"e_1_3_2_4_60_2","doi-asserted-by":"publisher","DOI":"10.1159\/000445328"},{"key":"e_1_3_2_4_61_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.01.022"},{"key":"e_1_3_2_4_62_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014113"},{"key":"e_1_3_2_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.03.011"},{"key":"e_1_3_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_3_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_3_2_5_6_2","article-title":"Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis.","volume":"6","author":"Pan K-L","year":"2017","unstructured":"Pan, K-L, Singer, DE, Ovbiagele, B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835.","journal-title":"J Am Heart Assoc"},{"key":"e_1_3_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"e_1_3_2_5_8_2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal safety of direct oral anticoagulants: a large population-based study.","volume":"152","author":"Abraham NS","year":"2017","unstructured":"Abraham, NS, Noseworthy, PA, Yao, X, et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014\u201322.e1.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.5954"},{"key":"e_1_3_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3189"},{"key":"e_1_3_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-05-0403"},{"key":"e_1_3_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.07.013"},{"key":"e_1_3_2_5_13_2","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation.","volume":"5","author":"Yao X","year":"2016","unstructured":"Yao, X, Abraham, NS, Sangaralingham, LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.","journal-title":"J Am Heart Assoc"},{"key":"e_1_3_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.117.017549"},{"key":"e_1_3_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.07.072"},{"key":"e_1_3_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701005"},{"key":"e_1_3_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.1087"},{"key":"e_1_3_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.1363"},{"key":"e_1_3_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.063"},{"key":"e_1_3_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501035"},{"key":"e_1_3_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278"},{"key":"e_1_3_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510991"},{"key":"e_1_3_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607887"},{"key":"e_1_3_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15192"},{"key":"e_1_3_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.029"},{"key":"e_1_3_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.025"},{"key":"e_1_3_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.010"},{"key":"e_1_3_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv730"},{"key":"e_1_3_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.035"},{"key":"e_1_3_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.05.038"},{"key":"e_1_3_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.03.007"},{"key":"e_1_3_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.20125"},{"key":"e_1_3_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021952"},{"key":"e_1_3_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02052-1"},{"key":"e_1_3_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2000.106648"},{"key":"e_1_3_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"e_1_3_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.110.977546"},{"key":"e_1_3_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.025"},{"key":"e_1_3_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.062"},{"key":"e_1_3_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu367"},{"key":"e_1_3_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31474-X"},{"key":"e_1_3_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141377"},{"key":"e_1_3_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22537"},{"key":"e_1_3_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.03.096"},{"key":"e_1_3_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy148"},{"key":"e_1_3_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.089"},{"key":"e_1_3_2_9_15_2","first-page":"487","article-title":"Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset.","volume":"2","author":"Garg A","year":"2016","unstructured":"Garg, A, Khunger, M, Seicean, S, et al. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. J Am Coll Cardiol EP. 2016;2:487\u201394.","journal-title":"J Am Coll Cardiol EP"},{"key":"e_1_3_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441901"},{"key":"e_1_3_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2011.06.014"},{"key":"e_1_3_2_9_18_2","unstructured":"Pfizer. Study of the blood thinner apixaban for patients who have an abnormal heart rhythm (atrial fibrillation) and expected to have treatment to put them back into a normal heart rhythm (cardioversion) (EMANATE). Available at: https:\/\/www.clinicaltrials.gov. Identifier: NCT02100228. Accessed November 22 2017."},{"key":"e_1_3_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3824"},{"key":"e_1_3_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2016.1267869"},{"key":"e_1_3_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2009.09.015"},{"key":"e_1_3_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707855"},{"key":"e_1_3_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019406"},{"key":"e_1_3_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.041"},{"key":"e_1_3_2_10_5_2","first-page":"200","article-title":"Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials.","volume":"1","author":"Al Halabi S","year":"2015","unstructured":"Al Halabi, S, Qintar, M, Hussein, A, et al. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. J Am Coll Cardiol EP. 2015;1:200\u20139.","journal-title":"J Am Coll Cardiol EP"},{"key":"e_1_3_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.02.015"},{"key":"e_1_3_2_10_7_2","first-page":"940","article-title":"Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: the results of the Cabana Multicenter International Randomized Clinical Trial. [abstract B-LBCT01-05].","volume":"15","author":"Packer DL","year":"2018","unstructured":"Packer, DL, Mark, DB, Robb, RA, et al. Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: the results of the Cabana Multicenter International Randomized Clinical Trial. [abstract B-LBCT01-05]. Heart Rhythm. 2018;15:940\u2013141.","journal-title":"Heart Rhythm"},{"key":"e_1_3_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454"},{"key":"e_1_3_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594"},{"key":"e_1_3_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"e_1_3_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.036"},{"key":"e_1_3_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.08.018"},{"key":"e_1_3_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"e_1_3_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22254"},{"key":"e_1_3_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.016"},{"key":"e_1_3_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.02.050"},{"key":"e_1_3_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.04.027"},{"key":"e_1_3_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00194-0"},{"key":"e_1_3_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.9.969"},{"key":"e_1_3_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(05)80227-3"},{"key":"e_1_3_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a060046"},{"key":"e_1_3_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901301"},{"key":"e_1_3_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"e_1_3_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"e_1_3_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.060"},{"key":"e_1_3_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv143"},{"key":"e_1_3_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1352"},{"key":"e_1_3_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.09.076"},{"key":"e_1_3_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.06.018"},{"key":"e_1_3_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000123"},{"key":"e_1_3_2_11_25_2","unstructured":"Bristol-Myers Squibb. A study of apixaban in patients with atrial fibrillation not caused by a heart valve problem who are at risk for thrombosis (blood clots) due to having had a recent coronary event such as a heart attack or a procedure to open the vessels of the heart. Available at: https:\/\/www.clinicaltrials.gov. Identifier: NCT02415400. Accessed November 1 2017."},{"key":"e_1_3_2_11_26_2","unstructured":"Daiichi Sankyo Inc. Edoxaban treatment versus vitamin K antagonist in patients with atrial fibrillation undergoing percutaneous coronary intervention (ENTRUST-AF-PCI). Available at: https:\/\/www.clinicaltrials.gov. Identifier: NCT02866175. Accessed November 1 2017."},{"key":"e_1_3_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht491"},{"key":"e_1_3_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circep.109.849638"},{"key":"e_1_3_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000057981.70380.45"},{"key":"e_1_3_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105575"},{"key":"e_1_3_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv115"},{"key":"e_1_3_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313600"},{"key":"e_1_3_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030583"},{"key":"e_1_3_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.003"},{"key":"e_1_3_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280521"},{"key":"e_1_3_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.028"},{"key":"e_1_3_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.002"},{"key":"e_1_3_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2012.08.043"},{"key":"e_1_3_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.20.2471"},{"key":"e_1_3_2_13_7_2","first-page":"1294","article-title":"Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions.","volume":"38","author":"Wong CX","year":"2017","unstructured":"Wong, CX, Ganesan, AN, Selvanayagam, JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017;38:1294\u2013302.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.11.045"},{"key":"e_1_3_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy117"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0000000000000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T19:50:45Z","timestamp":1715543445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":173,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7,9]]}},"alternative-id":["10.1161\/CIR.0000000000000665"],"URL":"https:\/\/doi.org\/10.1161\/cir.0000000000000665","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s10554-025-03330-z","asserted-by":"object"}]},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]},"assertion":[{"value":"2019-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}